Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.CERC · Entity 4936 | Director | June 15, 2021 | June 17, 2021 |
| CONTRAFECT CorpCFRX · Entity 116797 | Director | May 17, 2022 | May 18, 2022 |
| InspireMD, Inc.NSPR · Entity 7318 | Director | December 07, 2016 | December 08, 2016 |
| NexImmune, Inc.NEXI · Entity 89921 | Director | July 05, 2023 | July 07, 2023 |
| PDS Biotechnology CorpEDGE · Entity 7939 | Director | March 15, 2019 | March 18, 2019 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date June 15, 2021 · Filed June 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2031-06-15 | Direct | 40,000 |
Reported balance
After 2021-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-15 · Grant · Acquired 40,000 · Balance 40,000 F1: This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date.
CONTRAFECT Corp
Report date May 17, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2032-05-17 | Direct | 42,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 42,000 · Balance 42,000 F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date.
InspireMD, Inc.
Report date December 07, 2016 · Filed December 08, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2026-12-07 | Direct | 20,000 |
Reported balance
After 2016-12-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-12-07 · Grant · Acquired 20,000 · Balance 20,000 F1: The options vest in three equal annual installments, with 1/3 becoming exercisable on each of December 7, 2017, December 7, 2018 and December 7, 2019, subject to Mr. Barer's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in three equal annual installments, with 1/3 becoming exercisable on each of December 7, 2017, December 7, 2018 and December 7, 2019, subject to Mr. Barer's continued service.
NexImmune, Inc.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2033-07-04 | Direct | 44,983 |
Reported balance
After 2023-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 44,983 · Balance 44,983 |
PDS Biotechnology Corp
Report date March 15, 2019 · Filed March 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 678,075 |
Reported balance
After 2019-03-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-03-15 · Exercise / conversion · Acquired 20,000 · Balance 678,075 F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F2: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-15 · Exercise / conversion · Disposed 20,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F4: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F5: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.
F2: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F3: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.
F4: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.
F5: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 448,011 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 21,739 · Balance 448,011 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Exercise / conversion · Disposed 21,739 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aegerion Pharmaceuticals, Inc.
Report date November 29, 2016 · Filed December 01, 2016
Section 16 reporting ended · disclosed 2016-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 1
1 source rowRow 1 · 2016-11-29 · Disposition to issuer · Disposed 29,890 · Balance 0 F1: Disposed of in exchange for 30,665 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.25 · Expires 2021-05-05 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-11-29 · Disposition to issuer · Disposed 19,927 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.64 · Expires 2021-06-01 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-29 · Disposition to issuer · Disposed 9,988 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2022-06-05 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-29 · Disposition to issuer · Disposed 12,854 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.73 · Expires 2023-06-26 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-11-29 · Disposition to issuer · Disposed 14,700 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.55 · Expires 2024-06-26 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-11-29 · Disposition to issuer · Disposed 5,012 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.98 · Expires 2025-06-26 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-11-29 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in exchange for 30,665 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor.
Aevi Genomic Medicine, LLC
Report date February 03, 2020 · Filed February 05, 2020
Section 16 reporting ended · disclosed 2020-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2023-09-13 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2023-01-02 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-03 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: This option, which became exercisable on January 2, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2024-01-02 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-03 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: This option, which became exercisable on January 2, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2025-02-18 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-03 · Disposition to issuer · Disposed 80,000 · Balance 0 F4: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2026-04-15 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-03 · Disposition to issuer · Disposed 80,000 · Balance 0 F5: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-06-22 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-03 · Disposition to issuer · Disposed 80,000 · Balance 0 F6: This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2028-04-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F7: This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2023-09-13 | IndirectBy the Sol J. Barer 2013 Grantor Retained Annuity Trust III | 0 |
Reported balance
After 2020-02-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2022-10-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-03 · Disposition to issuer · Disposed 74,912 · Balance 0 F8: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger").
F2: This option, which became exercisable on January 2, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F3: This option, which became exercisable on January 2, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F4: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F5: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F6: This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F7: This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F8: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC | NexImmune, Inc. NEXI · Entity 89921 | PurchaseCommon Stock | 60,000 | $17.00 | $1,020,000.00 |
DisclosureSEC source: 0001209191-21-012354 · doc4.xml · nonDerivative · entry 6 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by B&S NexImmune Holdco LLC Disclosed balance after: 1,538,013 F4 · shares: Reflects shares purchased in the Issuer's initial public offering. F2 · ownership.nature: Mr. Barer is the father of Joshua Barer, who is the sole manager of B&S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer is also a member of Barer & Son Capital, LLC, which is a member of B&S NexImmune Holdco LLC, but he does not have voting or dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer disclaims beneficial ownership of the securities held by B&S NexImmune Holdco LLC except to the extent of his pecuniary interest therein. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionCommon Stock | 337,365 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012354 · doc4.xml · nonDerivative · entry 5 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by B&S NexImmune Holdco LLC Disclosed balance after: 1,478,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On February 17, 2021 (the "Closing"), the convertible promissory notes (the "Notes") became automatically convertible into shares of the Issuer's common stock. At the Closing, the principal amount of the Notes, plus accrued but unpaid interest thereon through February 17, 2021, converted into shares of the Issuer's common stock by dividing the principal and accrued but unpaid interest under such Note by the price per share obtained by dividing $125,000,000 by the Company's fully-diluted capitalization immediately prior to the IPO, assuming exercise or conversion of all convertible securities of the Company but excluding any shares issuable upon conversion of the Notes. F2 · ownership.nature: Mr. Barer is the father of Joshua Barer, who is the sole manager of B&S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer is also a member of Barer & Son Capital, LLC, which is a member of B&S NexImmune Holdco LLC, but he does not have voting or dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer disclaims beneficial ownership of the securities held by B&S NexImmune Holdco LLC except to the extent of his pecuniary interest therein. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionCommon Stock | 82,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012354 · doc4.xml · nonDerivative · entry 4 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by B&S NexImmune Holdco LLC Disclosed balance after: 1,140,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F2 · ownership.nature: Mr. Barer is the father of Joshua Barer, who is the sole manager of B&S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer is also a member of Barer & Son Capital, LLC, which is a member of B&S NexImmune Holdco LLC, but he does not have voting or dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer disclaims beneficial ownership of the securities held by B&S NexImmune Holdco LLC except to the extent of his pecuniary interest therein. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionCommon Stock | 164,408 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012354 · doc4.xml · nonDerivative · entry 3 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by B&S NexImmune Holdco LLC Disclosed balance after: 1,058,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F2 · ownership.nature: Mr. Barer is the father of Joshua Barer, who is the sole manager of B&S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer is also a member of Barer & Son Capital, LLC, which is a member of B&S NexImmune Holdco LLC, but he does not have voting or dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer disclaims beneficial ownership of the securities held by B&S NexImmune Holdco LLC except to the extent of his pecuniary interest therein. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionCommon Stock | 894,036 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012354 · doc4.xml · nonDerivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by B&S NexImmune Holdco LLC Disclosed balance after: 894,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F2 · ownership.nature: Mr. Barer is the father of Joshua Barer, who is the sole manager of B&S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer is also a member of Barer & Son Capital, LLC, which is a member of B&S NexImmune Holdco LLC, but he does not have voting or dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer disclaims beneficial ownership of the securities held by B&S NexImmune Holdco LLC except to the extent of his pecuniary interest therein. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionCommon Stock | 800,182 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012354 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,367,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:25 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 19,113 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010657 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,013 Underlying: Common Stock · 19,113 shares Expires 2025-02-11 F1 · derivative.exercise_date: These stock options will vest and become exercisable at the first anniversary of the vesting commencement date (2/11/21). Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 23,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-046579 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 23,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on August 11, 2017 and vested on August 11, 2020. F3 · derivative.expiration_date: Restricted share units were granted on August 11, 2017 and vested on August 11, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 23,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-046579 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:13 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000546 · edgar.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-06-18 F2 · derivative.exercise_price: Subject to the Reporting Person's continued service on such vesting date, the stock option will vest as follows: 1) 1/2 of the shares will vest on June 18, 2020, with an exercise price of $2.51; 2) the next 1/4 of the shares will vest upon the Issuer's stock price reaching a 50% premium to the Issuer's stock price on June 18, 2020, and will have the exercise price of the Issuer's stock price at that time; and 3) the final 1/4 of the shares will vest upon the Issuer's stock price reaching a 75% premium to the Issuer's stock price on June 18, 2020, and will have an exercise price of the Issuer's stock price at that time. F2 · shares: Subject to the Reporting Person's continued service on such vesting date, the stock option will vest as follows: 1) 1/2 of the shares will vest on June 18, 2020, with an exercise price of $2.51; 2) the next 1/4 of the shares will vest upon the Issuer's stock price reaching a 50% premium to the Issuer's stock price on June 18, 2020, and will have the exercise price of the Issuer's stock price at that time; and 3) the final 1/4 of the shares will vest upon the Issuer's stock price reaching a 75% premium to the Issuer's stock price on June 18, 2020, and will have an exercise price of the Issuer's stock price at that time. F2 · derivative.exercise_date: Subject to the Reporting Person's continued service on such vesting date, the stock option will vest as follows: 1) 1/2 of the shares will vest on June 18, 2020, with an exercise price of $2.51; 2) the next 1/4 of the shares will vest upon the Issuer's stock price reaching a 50% premium to the Issuer's stock price on June 18, 2020, and will have the exercise price of the Issuer's stock price at that time; and 3) the final 1/4 of the shares will vest upon the Issuer's stock price reaching a 75% premium to the Issuer's stock price on June 18, 2020, and will have an exercise price of the Issuer's stock price at that time. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:13 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000546 · edgar.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-18 F1 · shares: This stock option will be fully vested and exercisable on June 18, 2021, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 11:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 31,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036494 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 31,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 11, 2019 and vested on June 11, 2020. F3 · derivative.expiration_date: Restricted share units were granted on June 11, 2019 and vested on June 11, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 11:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 31,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036494 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 11:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 22,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035779 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,565 Underlying: Ordinary Shares · 22,565 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009876 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 14, 2017 and vested on February 14, 2020. F3 · derivative.expiration_date: Restricted share units were granted on February 14, 2017 and vested on February 14, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-009876 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:25 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerWarrant (Right to Buy) · Derivative | 74,912 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001192482-20-000127 · edgar.xml · derivative · entry 9 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,912 shares Expires 2022-10-17 F8 · derivative.exercise_date: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:25 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 100,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001192482-20-000127 · edgar.xml · derivative · entry 8 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-04-17 F7 · derivative.exercise_date: This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:25 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 80,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001192482-20-000127 · edgar.xml · derivative · entry 7 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2027-06-22 F6 · derivative.exercise_date: This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:25 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 80,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001192482-20-000127 · edgar.xml · derivative · entry 6 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2026-04-15 F5 · derivative.exercise_date: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:25 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 80,000 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001192482-20-000127 · edgar.xml · derivative · entry 5 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2025-02-18 F4 · derivative.exercise_date: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:25 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 15,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001192482-20-000127 · edgar.xml · derivative · entry 4 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-01-02 F3 · derivative.exercise_date: This option, which became exercisable on January 2, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:25 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 15,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001192482-20-000127 · edgar.xml · derivative · entry 3 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-01-02 F2 · derivative.exercise_date: This option, which became exercisable on January 2, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:25 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 200,000 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001192482-20-000127 · edgar.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Sol J. Barer 2013 Grantor Retained Annuity Trust III Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2023-09-13 F1 · derivative.exercise_date: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:25 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 200,000 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001192482-20-000127 · edgar.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2023-09-13 F1 · derivative.exercise_date: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:38 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001104659-20-011266 · tm206826d1_4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-02-03 F1 · derivative.exercise_date: The stock option will vest over over three years, with one-third of such option vesting on each of the first, second and third anniversaries of the date of grant. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:10 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | SaleCommon Stock | 4,098,752 | $0.13 | $549,232.77 |
DisclosureSEC source: 0001192482-19-000509 · edgar.xml · nonDerivative · entry 7 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:10 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | OtherCommon Stock | 2,551,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000509 · edgar.xml · nonDerivative · entry 6 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,098,752 F3 · ownership.direct: Pro rata distribution from Barer & Son Capital LLC, of which the Reporting Person is a member. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:10 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | OtherCommon Stock | 2,551,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000509 · edgar.xml · nonDerivative · entry 5 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Barer & Son Capital LLC Disclosed balance after: 0 F3 · ownership.nature: Pro rata distribution from Barer & Son Capital LLC, of which the Reporting Person is a member. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:10 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GiftCommon Stock | 365,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000509 · edgar.xml · nonDerivative · entry 4 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,547,732 F2 · ownership.direct: Shares gifted to the Reporting Person by the Sol J. Barer 2013 Grantor Retained Annuity Trust No. IV. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:10 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GiftCommon Stock | 365,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000509 · edgar.xml · nonDerivative · entry 3 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Grantor Retained Annuity Trust Disclosed balance after: 0 F2 · ownership.nature: Shares gifted to the Reporting Person by the Sol J. Barer 2013 Grantor Retained Annuity Trust No. IV. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:10 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GiftCommon Stock | 153,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000509 · edgar.xml · nonDerivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,181,878 F1 · ownership.direct: Shares gifted to the Reporting Person by the wife of the Reporting Person. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:10 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GiftCommon Stock | 153,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000509 · edgar.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Wife Disclosed balance after: 0 F1 · ownership.nature: Shares gifted to the Reporting Person by the wife of the Reporting Person. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 10:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 31,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036582 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,388 Underlying: Ordinary Shares · 31,388 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F2 · derivative.expiration_date: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 11:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | PurchaseOrdinary Shares | 104,500 | $9.60 | $1,003,409.00 |
DisclosureSEC source: 0001209191-19-034611 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,442 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.57 to $9.63, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 03, 2019 Filed Jun 3, 2019 15:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | PurchaseOrdinary Shares | 111,000 | $8.98 | $997,013.10 |
DisclosureSEC source: 0001209191-19-033779 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,942 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.915 to $9.095, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2019 Filed May 20, 2019 10:56 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031203 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on May 16, 2016 and vested on May 16, 2019. F3 · derivative.expiration_date: Restricted share units were granted on May 16, 2016 and vested on May 16, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 16, 2019 Filed May 20, 2019 10:56 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-031203 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 21:33 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-011903 · form4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F4 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F5 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 21:33 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-011903 · form4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 678,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F2 · ownership.direct: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. F2 · ownership.nature: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 03, 2018 Filed Sep 5, 2018 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-049510 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on October 7, 2015 and vested on September 3, 2018. F3 · derivative.expiration_date: Restricted share units were granted on October 7, 2015 and vested on September 3, 2018. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 03, 2018 Filed Sep 5, 2018 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-049510 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 16:07 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseCommon Stock | 2,551,020 | $0.96 | $2,448,979.20 |
DisclosureSEC source: 0001192482-18-000404 · edgar.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Barer & Son Capital LLC Disclosed balance after: 2,551,020 F1 · ownership.nature: The Reporting Person is a member of Barer & Son Capital LLC. As a member he has an economic interest in the assets owned by Barer & Son Capital LLC; however he has no control of the investment or disposition of such assets. Nevertheless, the reported shares may be deemed beneficially owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 11:51 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-025362 · form4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F2 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F3 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:37 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 40,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021592 · form4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 16:20 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 100,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001192482-18-000300 · edgar.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-04-17 F1 · date: The option award was granted on April 17, 2018 and was subject to forfeiture if stockholder approval of a proposed amendment to the Issuer's stock incentive plan to increase the number of shares reserved for issuance under the plan was not obtained. The Issuer's stockholders approved the amendment to the Issuer's stock incentive plan at the Issuer's annual meeting of stockholders on June 14, 2018. F2 · derivative.exercise_date: The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on April 17, 2019, then in 24 equal monthly installments on the 17th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer. Read SEC document |
| June 14, 2018 Filed Jul 18, 2018 16:23 UTC Amendment | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 100,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001192482-18-000346 · edgar.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-04-17 F1 · date: The option award was granted on April 17, 2018 and was subject to forfeiture if stockholder approval of a proposed amendment to the Issuer's stock incentive plan to increase the number of shares reserved for issuance under the plan was not obtained. The Issuer's stockholders approved the amendment to the Issuer's stock incentive plan at the Issuer's annual meeting of stockholders on June 14, 2018. F2 · derivative.exercise_date: This amendment is being filed to amend the vesting schedule of the option award. The entire option vests and becomes exercisable on April 17, 2019, subject to the reporting person's continued service with the Issuer. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 10:52 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 17,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036203 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,565 Underlying: Ordinary Shares · 17,565 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 5, 2018 and vest on June 5, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 5, 2018 and vest on June 5, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 16:15 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseWarrant (right to buy) · Derivative | 74,912 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001144204-17-053025 · tv477161_4.xml · derivative · entry 4 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,912 Underlying: Common Stock · 74,912 shares Expires 2022-10-17 Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 16:15 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseCommon Stock | 421,032 | $1.26 | $530,500.32 |
DisclosureSEC source: 0001144204-17-053025 · tv477161_4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,028,032 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.